Back to Search Start Over

Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis.

Authors :
Cho HJ
Lim YJ
Kim J
Koh WJ
Song CH
Kang MW
Source :
BMC infectious diseases [BMC Infect Dis] 2020 Jan 29; Vol. 20 (1), pp. 81. Date of Electronic Publication: 2020 Jan 29.
Publication Year :
2020

Abstract

Background: Macrophages play a key role in the infection process, and alternatively activated macrophages (M2 polarization) play important roles in persistent infection via the immune escape of pathogens. This suggests that immune escape of pathogens from host immunity is an important factor to consider in treatment failure and multidrug-resistant tuberculosis (MDR-TB)/extensively drug-resistant tuberculosis (XDR-TB). In this study, we investigated the association between macrophage polarization and MDR-TB/XDR-TB and the association between macrophage polarization and the anti-TB drugs used.<br />Methods: iNOS and arginase-1, a surface marker of polarized macrophages, were quantified by immunohistochemical staining and imaging analysis of lung tissues of patients who underwent surgical treatment for pulmonary TB. Drug susceptibility/resistance and the type and timing of anti-tuberculosis drugs used were investigated.<br />Results: The M2-like polarization rate and the ratio of the M2-like polarization rate to the M1-like polarization rate were significantly higher in the MDR-TB/XDR-TB group than in the DS-TB group. The association between a high M2-like polarization rate and MDR-TB/XDR-TB was more pronounced in patients with a low M1-like polarization rate. Younger age and a higher M2-like polarization rate were independent associated factors for MDR-TB/XDR-TB. The M2-like polarization rate was significantly higher in patients who received anti-TB drugs containing pyrazinamide continuously for 4 or 6 weeks than in those who received anti-TB drugs not containing pyrazinamide.<br />Conclusions: The M2-like polarization of macrophages is associated with MDR-TB/XDR-TB and anti-TB drug regimens including pyrazinamide or a combination of pyrazinamide, prothionamide and cycloserine.

Details

Language :
English
ISSN :
1471-2334
Volume :
20
Issue :
1
Database :
MEDLINE
Journal :
BMC infectious diseases
Publication Type :
Academic Journal
Accession number :
31996142
Full Text :
https://doi.org/10.1186/s12879-020-4802-9